**Non-neutropenic fever in children with cancer: a scoping review of management and outcome.**

Zoe Allaway1, Robert S Phillips2,3 and Gabrielle M Haeusler1,4,5

*1Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 2Centre for Reviews and Dissemination, University of York, York, United Kingdom; 3Leeds General Infirmary, Leeds Teaching Hospitals National Health Services Trust, Leeds, United Kingdom; 4Paediatric Integrated Cancer Service, Melbourne, Victoria, Australia; 5Department of Infectious Diseases, Royal Children’s Hospital, Parkville, Victoria*

**Corresponding Author:** Zoe Allaway

Address: Level 13, Department of Infectious Diseases, VCCC, 305 Grattan Street Melbourne, VIC 3000

Phone: (03) 8559 8614

Fax: (03) X

Email: zoe.allaway@petermac.org

**Word Count:** 2553

**Tables:** 3

**Figures:** 2

**Keywords:** non-neutropenic fever, paediatric oncology, bacteraemia, infectious diseases, health services research

**Abbreviations key:**

|  |  |
| --- | --- |
| Absolute Neutrophil Count | ANC |
| Acute Lymphoblastic Leukaemia | ALL |
| American Society of Pediatric Hematology/Oncology | ASPHO |
| Central Venous Catheter | CVC |
| Clinical Decision Rule | CDR |
| C-Reactive Protein | CRP |
| Emergency Department | ED |
| Febrile Neutropenia | FN |
| Intensive Care Unit | ICU |
| Non-Neutropenic Fever | NNF |
| Upper Respiratory Tract Infection | URTI |

**Non-neutropenic fever in children with cancer: a scoping review of management and outcome.**

Zoe Allaway1, Robert S Phillips2,3 and Gabrielle M Haeusler1,4,5

*1Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 2Centre for Reviews and Dissemination, University of York, York, United Kingdom; 3Leeds General Infirmary, Leeds Teaching Hospitals National Health Services Trust, Leeds, United Kingdom; 4Paediatric Integrated Cancer Service, Melbourne, Victoria, Australia; 5Department of Infectious Diseases, Royal Children’s Hospital, Parkville, Victoria*

**Introduction**

In the absence of a functional immune system, be it disease or treatment related, infection in children with cancer is typically heralded by fever alone. While the barriers and response to infection are a complex interplay between the innate and adaptive immune system, chemotherapy-induced neutropenia remains one of the most important risk factors for a severe, invasive bacterial infection.(1, 2) The duration and depth of neutropenia further influences risk, with as many as 80% of patients developing a severe infection after three weeks of profound neutropenia in the pre-antibiotic era.(2) Given the potential for severe infection and adverse outcome, much of the research has focused on the clinical syndrome of fever and neutropenia (FN), with very few studies addressing non-neutropenic fever (NNF) in this population.(3) A detailed understanding of the causes, outcomes and optimal treatment of NNF is increasingly important with the development of new generation cancer therapies that tend to cause less neutropenia but are still associated with a risk of infection.(4, 5)

The frequency of NNF during paediatric cancer treatment is largely unknown but likely varies according to type of malignancy and treatment. In a national prospective study of FN in Australia, over half of emergency department (ED) presentations in children with cancer and fever were due to NNF.(Haeusler GM, verbal communication, 04/10/2018) Results of a data linkage study from the United States suggest similarly high rates of NNF presentations to the ED.(6) This burden of NNF has been previously unrecognised, as evidenced by the paucity of guidelines, care pathways and dedicated research in this area.(3, 7) Furthermore, little is known about the cause of fever, frequency of bacteraemia and outcomes of these patients.

The aim of this scoping review is to bring together all available studies that provide clinical details about children with cancer and NNF. In particular, our objectives are to describe the rates of bacteraemia, risk factors for infection, empiric antibiotic management and outcomes of NNF in this population.

**Methods**

As a scoping review, this study undertook a comprehensive electronic search strategy across multiple databases, included studies relevant to the focussed clinical question, and undertook a synthesis to describe the nature of the existing research, strengths and limitations of the studies, and make conclusions regarding clinical and research implications. Simple meta-analysis of proportions was undertaken using the binomial model developed by Simmonds (8), with 95% confidence intervals estimated by bootstrapping with replacement in 1000 samples.

The search was developed using three primary research terms, including fever, cancer diagnosis and non-neutropenia. This search was extended to include possible variations and synonyms of key search terms. Electronic databases searched included MEDLINE (Ovid), EMBASE (Ovid) and PubMed. No language or date filters were applied. Reference lists of relevant systematic reviews and included articles were also reviewed.

Two reviewers independently screened the title and abstract of studies for inclusion. Disagreements were resolved by consensus. The search occurred on 25 September 2018. Studies were included in this review if they reported clinical details of paediatric patients (age <21) with cancer or haematological malignancy and NNF. Non-neutropenia was defined as absolute neutrophil count (ANC) greater than or equal to 500 cells per microliter. Fever was defined according to the original study. For studies including episodes of FN and NNF, only those were included in the analysis if results of NNF were reported separately.

**Results**

A total of 646 titles and abstracts were reviewed, of which 83 full text articles were retrieved.

From this, 16 relevant articles, describing 15 studies, were identified for inclusion in this review (Figure 1).(3, 6, 7, 9-24) No dedicated NNF treatment guidelines were identified in this search. One survey of practice was found but not included as patient level data were not reported.(23)

The inclusion criteria across the studies included in this review varied. Notably, nine (60%) studies only included patients with a central venous catheter (CVC) *in situ*.(11-17, 19, 21) The type of CVC also varied across the studies with implanted Ports more common in six (11, 13, 15, 16, 19, 21) while tunnelled external CVC were more common in two, albeit older, studies (12, 17) (type not reported in 7). Acute lymphoblastic leukaemia (ALL) was the most common underlying cancer diagnosis across all studies (not reported in 4).(11-17, 19-22)

Seven different definitions of fever were used with the most common being a single temperature greater than or equal to 38.0 degrees Celsius (4 studies).(18, 19, 21, 22) Conversely only three different definitions of non-neutropenia were used with the most common being an ANC equal to or greater than 500 cells/μL (13 studies).(7, 10-21) A definition of bacteraemia was reported in eight studies (12, 13, 15-17, 19, 21, 22) with only four studies requiring common commensals to be cultured more than once.(13, 15, 16, 21)

***Frequency of NNF***

In five studies, NNF episodes were reported as a subset of all febrile episodes (i.e. both febrile neutropenia and NNF reported).(10, 17, 18, 20, 22) Of these, NNF accounted for between 38 and 49% of all febrile episodes.

***Cause of fever***

Across the 15 studies, of the pooled average rate of bacteraemia was 8.2% (95% CI 5.3% to 13%) over 4106 NNF episodes (see Fig Z). Overall, eleven studies reported a bacteraemia rate less than 10%.(7, 11-16, 18, 19, 21, 22) In studies that excluded common commensals unless cultured more than once, the bacteraemia rate ranged from 4 to 10%, pooled average 6.3% (95%CI 4.6% to 8.5%).(12, 13, 15, 16, 21) In the remaining ten studies that either did not report the definition of bacteraemia or included common commensals cultured once, the bacteraemia occurred between 3 and 32% of NNF episodes, pooled average 9.7% (95% CI 5.1% to 18.0%).(7, 10, 11, 14, 17-20, 22, 24) Of the five studies that included patients without a CVC, rates of bacteraemia were not analysed separately from patients with a CVC in situ in the non-neutropenic population.(7, 10, 18, 22, 24)

Notably, estimated mid-year of the data collection for each study was a significant predictor in meta-regression, with more modern studies having a lower proportion of bacteraemias (OR of each year from 1986 onwards 0.93; 95% CI 0.90 to 0.96)

****

In studies reporting the type of bacteraemia, including four that that excluded common commensals cultured once, Gram positive bacteria were the most frequently identified (11-15, 17, 19, 21) Overall, coagulase negative staphylococci were the most common cause of bacteraemia, followed by *Enteroccocus* spp, *Staphylococcus aureus*, *Streptococcus pneumoniae* and oral viridans streptococci. Among Gram negative bacteria, Enterobacteriaceae were the most common followed by *Pseudomonas* spp and *Acinitobacter* spp. A total of seven fungal blood stream infections (*Candida albicans* in 3; *Candida* species in 1; *Candida parapsilosis* in 2; *Trichosporin spp* in 1) were reported across five of the nine studies that provided details on the type of organisms.(11, 14, 15, 17, 21)

Limited antibiotic susceptibility details were provided in five studies.(11, 12, 15, 19, 21) The proportion of bacteraemia episodes with inherent or acquired resistance to third generation cephalosporins, namely ceftriaxone, ranged from 46 to 75%. In one study, 12 out of 16 (75%) high risk bacteria (including Enterobacteriacea, *S. aureus*, oral viridans streptococci, *S. pneumoniae*) were susceptible to ceftriaxone compared to three out of 17 (18%) low risk bacteria (including CoNS, *Enterococcus* spp, *Bacillus* spp).(19)

Five studies provided additional details on other infective causes of fever with upper respiratory tract infections most frequent, occurring in between 14 and 63% of episodes.(11, 18, 19, 21, 22)

***Outcome***

Overall the outcomes of NNF appear favourable (Table 1). Where reported, there were no deaths and admission to the Intensive Care Unit (ICU) was infrequent.(7, 10, 12-15, 18, 19) Five studies described a risk stratified approach to treatment based on a combination of clinical and biochemical parameters, including C-reactive protein (CRP) ≥50μg/mL, toxic or focal signs of bacterial infection, sepsis or chills.(7, 10-13) Importantly, there were no adverse outcomes described with this approach, which included reduced intensity treatment for patients identified as low risk.

***Empiric antibiotic treatment and location***

Eight studies provided details on empiric NNF antibiotic treatment, with ceftriaxone the most common agent used (Table 2).(10-13, 15, 17, 19, 21) Across the four studies that reported duration of treatment, no site routinely exceeded 48 to 72 hours.(11, 12, 15, 19) The outpatient setting was most frequently employed to monitor these patients and provide additional doses of antibiotics.

In two studies, antibiotics were only administered to patients with rigors or unwell appearance, resulting in subset of patients on no antibiotics for the NNF episode.(7, 13) Notably, only 7 of 24 episodes of NNF with bacteraemia that were not commenced on antibiotics required readmission in one study (13) and there were no admissions to ICU or deaths with this approach across both.(7, 13)

***Risk factors for bacteraemia***

Five studies investigated clinical characteristics associated with bacteraemia in patients with NNF (Table 3).(11, 13, 15, 19, 21) Type of CVC was significantly associated with bacteraemia in four out of five studies with an increased risk observed in patients with a tunnelled external CVC (OR 4.0 to 14) or PICC (OR 4.0), compared to implantable ports.(15, 19, 21, 24) Across three studies the presence of hypotension, fluid bolus requirement or chills or rigors was also significantly associated with bacteraemia.(11, 15, 21) Other significant associations included height of temperature (13, 15) and absence of upper respiratory tract infection (URTI) symptoms.(15, 21)

Only one clinical decision rule (CDR), designed to predict bacteraemia in children with cancer and NNF, was identified. This rule (EsVan) was retrospectively derived in a single centre and has undergone retrospective, multisite validation.(15, 16) The model incorporated 12 weighted clinical variables and had moderate discrimination with a C-statistic of 0.898. In validation the c-statistic fell to 0.687 for the original model and 0.721 for a modified CDR (EsVan2) which excludes the variables diagnosis and location of onset of fever. Of note, the EsVan2 model performed better for prediction of bacteraemia with high-risk organisms (defined as Gram negative or *Staphylococcus aureus*) with a C-statistic of 0.841.(9, 16)

**Discussion**

In contrast to the breadth of paediatric FN research, very few studies have explored the causes, treatment and outcomes of NNF in children with cancer. Although only 15 studies were identified in this review, the rate of bacteraemia appears to be less than 10% and very few adverse outcomes were described. Treatment approaches also appear similar, with at least four sites routinely providing daily antibiotics in the outpatient setting for 24 to 72 hours for patients who are clinically stable.

There is no consensus definition for NNF. While most studies included in this review defined neutropenia as an ANC greater than or equal to 500 cells/μL, many different definitions for fever were reported. This variation is not surprising given international consensus was unable to be achieved on a definition of FN in paediatric cancer patients.(25) While the impact of varying temperature thresholds for fever is unknown, temperature height on presentation with NNF was an independent predictor of bacteraemia in two studies (13, 15).

Although the true incidence of NNF is unknown, this review suggests it accounts for up to 50% of febrile presentations in children with cancer. Results of a US-based data linkage study indicate that NNF may actually be more common than this, accounting for over half of febrile presentations to the emergency department.(6) However, despite the frequency with which NNF appears to occur, no published guidelines for the investigation and management of NNF were identified. An international paediatric FN evidence-based guideline is available, although does not specifically address recommendations for patients with an ANC greater than 500cells/μL.(26, 27). The paucity of studies in this area, as well as the absence of dedicated guidelines, likely explains the considerable variation in approach to the evaluation and treatment of NNF among a large group (n=316) of American Society of Pediatric Hematology/Oncology (ASPHO) members.(23) In this survey of practice, a number of different empiric antibiotic combinations were used and the presence of a CVC, or known source of infection had variable impact on decision to start antibiotics. An overview of the treatment approach to NNF is available which emphasises adherence to local sepsis or potential central venous access device associated blood stream infection protocols, where relevant.(3)

In most studies, bacteraemia was documented in less than 10% of NNF episodes. The three studies that reported much higher rates (between 24 and 32%) included patients treated from 1989 to 1996 and improvements in supportive care and CVC maintenance may explain this reduction.(10, 17, 24) The type of CVC also appears to influence the risk of bacteraemia, with significantly higher rates seen in patients with tunnelled-external CVCs compared to implantable Ports across four out of the five studies investigating this association.(13, 15, 19, 21, 24) Given the high proportion of NNF episodes with a CVC it is not surprising that Gram positive bacteria, frequently associated with CVC infections, were the most common pathogens isolated.(find ref) Ongoing improvements in CVC care have the potential to further reduce infections in this vulnerable population.(find ref) Bacteraemia with *Streptococcus pneumoniae* was also documented in these patients, and while serotypes were not reported, this also highlights the importance of vaccination during cancer treatment as part of the infection-prevention bundle.(28)

In keeping with results of the ASPHO survey of practice, ceftriaxone was the most commonly used empiric monotherapy for NNF.(11, 14, 15, 19, 21, 23) This is presumably due to the ease of administration and concern over the adverse effects of Gram negative sepsis in this population. Notably, although as many as 75% of all bacteraemia episodes had inherent or acquired resistance to ceftriaxone, very few adverse outcomes were reported. While these results suggest daily ceftriaxone may be safe to use, consideration should be given to local susceptibility patterns. Furthermore, some studies described a risk stratified approach to treatment with alternative ‘broad-spectrum’ empiric antibiotics used in patients who were unwell, or had chills or rigors.(11-13) As bacteraemia with *Pseudonomas* spp was reported, empiric NNF treatment strategies should cover for this pathogen in patients with severe sepsis or clinical instability.

There was some commonality in the clinical features associated with bacteraemia, in particular type of CVC, height of temperature and presence of chills or rigors. Bacteraemia also appears less likely in patients with NNF and URTI symptoms. As this was the most common infective cause of NNF, treatment algorithms incorporating this clinical variable have the potential to dramatically reduce antibiotic exposure in this population.

In contrast to the 27 CDRs the have been derived for prediction of infection or adverse outcome in children with cancer and FN, only one NNF CDR has been developed.(25, 29, 30) This rule, designed to predict bacteraemia, incorporates up to 12 clinical variables routinely available to clinicians when assessing these patients in the emergency department.(15) In a multisite validation study, albeit retrospective, the CDR retained its discriminatory ability for the prediction of high-risk bacteraemia, arguably the most serious and potentially life-threatening causes of NNF.(9, 16) Further research is required to determine the clinical applicability of this CDR to children outside the United States as well as its clinical impact. Based on available evidence, the latter is likely to be high as reduced intensity treatment, including no antibiotics, appears safe in patients with NNF considered lower risk of infection.(7, 11-13)

This is the first time that the common condition of NNF has been systematically reviewed. While every effort was made to identify all relevant studies of children with cancer and NNF, the absence of accepted terminology and a definition of this syndrome means some publications may have been missed. Studies included in this review also comprised patients treated across three decades, where changes in chemotherapy, supportive care and CVC choice and maintenance, limit direct comparisons and conclusions that can be drawn.

The limited research investment into NNF, together with the apparent variations in practice and paucity of guidelines, suggest that the frequency and impact of this syndrome has been largely unappreciated. Reassuringly, outcomes appear favourable and patients have been managed successfully in the outpatient setting. Further research is required to determine the most appropriate management strategies including antibiotic type and duration as well as the true clinical, economic and quality of life impact of reduced intensity treatment of NNF. Existing risk factors of bacteraemia, as well as the NNF CDR (EsVan) should undergo further prospective validation and local and international guidelines developed to reduce unnecessary variations in practice. A collaborative, international approach, similar to what has been achieved for FN, would enable large, multisite datasets to more rapidly inform practice change and further improve the management of fever and infection in children with cancer.(26, 31, 32)

**References**

1. Chaplin DD. Overview of the immune response. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S3-23.

2. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64(2):328-40.

3. Morgan JE. Fifteen minute consultation: Fever in children being treated for cancer. Arch Dis Child Educ Pract Ed. 2018.

4. Teh BW, Harrison SJ, Pellegrini M, Thursky KA, Worth LJ, Slavin MA. Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infection. Blood Rev. 2014;28(2):75-86.

5. Teh BW, Harrison SJ, Worth LJ, Thursky KA, Slavin MA. Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis. Eur J Cancer. 2016;67:21-37.

6. L. ME, Amber S, Achamyeleh G, Rajen M, Lillian S, L. MM. Why pediatric patients with cancer visit the emergency department: United States, 2006–2010. Pediatr Blood Cancer. 2015;62(3):490-5.

7. Wu N, Muller W, Morgan E. Outcomes of observation without Empiric IV antibiotics in febrile, non-neutropenic pediatric oncology patients. Pediatric Blood and Cancer. 2018;65 (Supplement 1):S164-S5.

8. Simmonds MC, Higgins JP. A general framework for the use of logistic regression models in meta-analysis. Stat Methods Med Res. 2016;25(6):2858-77.

9. Erratum. Cancer. 2018;124(8):1841-4.

10. Abrahamsson J, Pahlman M, Mellander L. Interleukin 6, but not tumour necrosis factor-alpha, is a good predictor of severe infection in febrile neutropenic and non-neutropenic children with malignancy. Acta Paediatr. 1997;86(10):1059-64.

11. Ali BA, Hirmas N, Tamim H, Merabi Z, Hanna-Wakim R, Muwakkit S, et al. Approach to Non-Neutropenic Fever in Pediatric Oncology Patients-A Single Institution Study. Pediatr Blood Cancer. 2015;62(12):2167-71.

12. Averbuch D, Makhoul R, Rotshild V, Weintraub M, Engelhard D. Empiric treatment with once-daily cefonicid and gentamicin for febrile non-neutropenic pediatric cancer patients with indwelling central venous catheters. J Pediatr Hematol Oncol. 2008;30(7):527-32.

13. Bartholomew F, Aftandilian C, Andrews J, Gutierrez K, Luna-Fineman S, Jeng M. Evaluation of febrile, nonneutropenic pediatric oncology patients with central venous catheters who are not given empiric antibiotics. J Pediatr. 2015;166(1):157-62.

14. Beauchemin MM, Fernbach AE, Lopez I, Kelly KM, Sulis ML. Risk factors for bacteremia in pediatric patients with cancer and non-neutropenic fever. Pediatric Blood and Cancer. 2012;59 (6):1113.

15. Esbenshade AJ, Pentima MC, Zhao Z, Shintani A, Esbenshade JC, Simpson ME, et al. Development and validation of a prediction model for diagnosing blood stream infections in febrile, non-neutropenic children with cancer. Pediatr Blood Cancer. 2015;62(2):262-8.

16. Esbenshade AJ, Zhao Z, Aftandilian C, Saab R, Wattier RL, Beauchemin M, et al. Multisite external validation of a risk prediction model for the diagnosis of blood stream infections in febrile pediatric oncology patients without severe neutropenia. Cancer. 2017;123(19):3781-90.

17. Gorelick MH, Owen WC, Seibel NL, Reaman GH. Lack of association between neutropenia and the incidence of bacteremia associated with indwelling central venous catheters in febrile pediatric cancer patients. Pediatr Infect Dis J. 1991;10(7):506-10.

18. Ke ZY, Xu L, Zhang TT, Mo YL, Huang LB, Zhang XL, et al. A prospective study of febrile episodes in inpatient children on chemotherapy. Pediatr Infect Dis J. 2010;29(10):968-70.

19. Kelly MJ, Vivier PM, Panken TM, Schwartz CL. Bacteremia in febrile nonneutropenic pediatric oncology patients. Pediatr Blood Cancer. 2010;54(1):83-7.

20. Mahmood S, Revesz T, Mpofu C. Febrile episodes in children with cancer in the United Arab Emirates. Pediatr Hematol Oncol. 1996;13(2):135-42.

21. Moskalewicz RL, Isenalumhe LL, Luu C, Wee CP, Nager AL. Bacteremia in nonneutropenic pediatric oncology patients with central venous catheters in the ED. Am J Emerg Med. 2017;35(1):20-4.

22. Rahiala J, Perkkio M, Riikonen P. Infections occurring during the courses of anticancer chemotherapy in children with ALL: a retrospective analysis of 59 patients. Pediatr Hematol Oncol. 1998;15(2):165-74.

23. Salzer W, Steinberg SM, Liewehr DJ, Freifeld A, Balis FM, Widemann BC. Evaluation and treatment of fever in the non-neutropenic child with cancer. J Pediatr Hematol Oncol. 2003;25(8):606-12.

24. Sandoval C, Giamelli J, Visintainer P, Jayabose S, Ozkaynak MF, Tugal O, et al. #605 Management of febrile non-neutropenic episodes in pediatric oncology patients. J Pediatr Hematol Oncol. 1998;20(4):374.

25. Haeusler GM, Thursky KA, Slavin MA, Mechinaud F, Babl FE, Bryant P, et al. External Validation of Six Pediatric Fever and Neutropenia Clinical Decision Rules. Pediatr Infect Dis J. 2018;37(4):329-35.

26. Lehrnbecher T, Robinson P, Fisher B, Alexander S, Ammann RA, Beauchemin M, et al. Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update. J Clin Oncol. 2017;35(18):2082-94.

27. Lehrnbecher T, Phillips R, Alexander S, Alvaro F, Carlesse F, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol. 2012;30(35):4427-38.

28. Crawford NW, Balloch A, Tikkanen L, Merchinaud F, Downie P, Buttery JP. Pneumococcal conjugate vaccine administration during therapy for pediatric leukemia. Pediatr Infect Dis J. 2015;34(1):e9-15.

29. Phillips B, Wade R, Stewart LA, Sutton AJ. Systematic review and meta-analysis of the discriminatory performance of risk prediction rules in febrile neutropaenic episodes in children and young people. Eur J Cancer. 2010;46(16):2950-64.

30. Phillips RS, Lehrnbecher T, Alexander S, Sung L. Updated Systematic Review and Meta-Analysis of the Performance of Risk Prediction Rules in Children and Young People with Febrile Neutropenia. PLoS One. 2012;7(5):e38300.

31. Lehrnbecher T, Phillips R, Alexander S, Alvaro F, Carlesse F, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol. 2012;30(35):4427-38.

32. Phillips RS, Sung L, Ammann RA, Riley RD, Castagnola E, Haeusler GM, et al. Predicting microbiologically defined infection in febrile neutropenic episodes in children: global individual participant data multivariable meta-analysis. Br J Cancer. 2016;114(6):623-30.